Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib a Swedish model application

Acta Oncologica

Volumn 49, Issue 6, 2010, Pages 851-858

  Ghatnekar, Ola ^a   Hjalte, Frida ^a   Taylor, Matthew ^b  

^a SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB;

ADULT; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PLEURA EFFUSION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIMULATION; SWEDEN; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MARKOV CHAINS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUALITY-ADJUSTED LIFE YEARS; SWEDEN; THIAZOLES; TREATMENT OUTCOME;

EID: 77954507393     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.495132     Document Type: Article

References (27)

1. Svenska KML-gruppen. Nationella riktlinjer för diagnostik och behandling av kronisk myeloisk leukemi. [cited 2008]. Available from: http://www.sfhem.se/klm.
2. Regional Oncology Centre in Uppsala/Örebro region. Chronic Myeloid Leukemia National Register for CML. Data report no.3 for 2002-2006. [cited 2008]. Available from: http://www.roc.se.
3. Aoki E, Kantarjian H, ÓBrien S. Correlation of different responses to imatinib on survival of patients with chronic myelogenous leukemia (CML) in accelerated (AP) and blast phase (BP). Blood 2005;106:1103.
4. Kantarjian H, Sawyers CL, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. (erratum in NEJM 2002;346:1923). NEJM 2002; 346:645-652
5. Garside R, Round A, Dalziel K, Stein K, Royle P. The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukemia: A systematic review. Health Technol Assess 2002; 6:1-151.
6. Frame D. New strategies in controlling drug resistance. J Manage Care Pharm 2007;13:S13-S17.
7. Deininger MW. Milestones and monitoring in patients with CML treated with imatinib. Hematology 2008; 419-426
8. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-1820
9. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003;101:473-475 (Pubitemid 36077567)
10. Hazarika M, Jiang X, Liu Q, Lee SL, Ramchandani R, Garnett C, et al. Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 2008;14:5325-5331
11. Kantarjian HM, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of fi rst-line imatinib: A randomized phase 2 trial. Blood 2007;109:5143-5150
12. Brosa M, Taylor MJ, Staginnus U, Meno Duran A, Cerri KH, Cervantes F. Cost-effectiveness of dasatinib vs imatinib 800 mg/day in patients with imatinib-resistant chronic myeloid leukemia in Spain. Value Health 2007;10:A283.
13. Logman F, Taylor MJ, Neumann K, Kutikova L, Cerri KH, Van Hout B, et al. Cost-utility analysis of dasatinib in patients after fi rst-line failure of imatinib in chronic myeloid leukemi (CML) in Austria. Value Health 2007;10:A325.
14. Taylor MJ, Minda K, Cerri KH, Davis C, Kan HJ, Ray S. An economic evaluation of dasatinib as a treatment for chronic phase chronic myeloid leukemia in Scotland. Value Health 2007;10:A233.
15. Taylor MJ, Devercelli G, Ray S, Holyoke T, Cortes J, Kan H, et al. An economic evaluation of dasatinib for the treatment of chronic phase chronic myelogenous leukaemia in imatinib-resistant patients in Scotland. Value Health. Under review.
16. Statistics Sweden. Life tables 2001-2005, annual mortality risks (in Swedish). 2006.
17. LFN. General guidelines for economic evaluations from the Pharmaceutical Benefi ts Board. 2003;LFNAR 2003:2.
18. Holowiecki AJ, Konopka L, Kopera M, Bober G, Kruzel T, Ceglarek B, et al. Effi cacy of imatinib patients with chronic myeloid leukemia in late chronic phase who are hematologically or cytogenetically resistant or refractory to interferon alfa. Phase II study of the Polish Adult Leukemia Group. Am Soc Hematol 45th Annual Meeting and Exposition. 2006 (Abstract).
19. Silver RT, Talpaz M, Sawyers CL, Druker BJ, Hochhaus A, Schiffer CA, et al. Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials. Blood 2004; 104:23.
20. Levy AR, Szabo SM, Tabberer M, Davis C. Utility values for health states for chronic myelogenous leukaemia (CML): Estimates from laypersons in Australia, the United Kingdom (UK) and Canada. Value Health 2007;10:A344.
21. Dalziel K, Round A, Stein K, Garside R, Price A. Effectiveness and cost-effectiveness of imatinib for fi rst-line treatment of chronic myeloid leukaemia in chronic phase: A systematic review and economic analysis. Health Technol Assess 2004; 8:1-120.
22. FASS. FASS 2008 (Pharmaceutical Specialties in Sweden). Stockholm: Läkemedelsindustriföreningen (LIF); 2008.
23. Southern Regional Health Care Committee. Regional tariffs and fees for the Southern Health Care Region, 2008 (in Swedish). 2008.
24. Income Distribution Survey 2003. Income distribution survey 2003, HE 21 SM 0501. Örebro: Statistics Sweden; 2006. Contract No.: Document Number.
25. Ekman M. Consumption and production by age in Sweden: Basic facts and health economic implications. Studies in health economics: Modelling and data analysis of costs and survival. Stockholm: Stockholm School of Economics; 2002.
26. Persson U, Hjelmgren J. Health services need knowledge of how the public values health. Läkartidningen 2003; 100:3436-3437
27. Shah NP, Kantarjian HM, Kim D-W, Réa D, Dorlhiac- Llacer PE, Milone JH, et al. Intermittent target inhibition with Dasatinib 100 mg once daily preserves effi cacy and improves tolerability in imatinib-resistent and -intolerent chronic-phase chronic myeloid leukemia. J Clin Oncol 2008; 26:3204-3212